Form 4: Krystal Biotech CEO Reports Significant Equity Transactions

Krystal Biotech's President and CEO, Krish S. Krishnan, reported multiple equity transactions including RSU and PSU vestings, tax withholdings, and new stock option and RSU grants.

Summary

• Krish S. Krishnan, President and CEO of Krystal Biotech, Inc., reported the vesting of 8,750 Restricted Stock Units (RSUs) and 26,250 Performance Stock Units (PSUs) on February 27, 2026.
• An additional 5,725 RSUs vested for Mr. Krishnan on the same date.
• Shares totaling 3,981, 11,942, and 2,605 were surrendered to the company for tax withholding upon the respective vestings, based on a closing price of $275.64 per share.
• Mr. Krishnan also received new grants of 45,249 stock options and 18,140 RSUs on February 27, 2026, which will vest in annual installments starting February 27, 2027.
• His spouse, Suma M. Krishnan, had 22,500 PSUs and 4,000 RSUs vest on February 27, 2026, with 10,236 and 1,820 shares, respectively, surrendered for tax withholding at $275.64 per share.
• All performance criteria for the PSUs granted on February 29, 2024, to both Mr. Krishnan and his spouse were achieved.
• Following these transactions, Krish S. Krishnan directly beneficially owns 1,500,253 shares of common stock, and indirectly owns 1,428,155 shares through his spouse, 90,000 shares through the Krishnan Spousal Trust, and 50,000 shares through the Krishnan Family Trust.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively as it reflects the achievement of performance criteria for executive compensation and the granting of new equity awards, which aligns management's long-term interests with shareholders.

Positives

• Performance criteria for 52,500 PSUs granted to Krish S. Krishnan and 45,000 PSUs granted to his spouse were fully achieved for the year ended December 31, 2024, leading to their vesting.
• New grants of 45,249 stock options and 18,140 RSUs to Krish S. Krishnan indicate continued long-term incentive and alignment with company performance.
• The vesting of a significant number of RSUs and PSUs represents successful execution and retention of key leadership.

Negatives

• A total of 18,528 shares of common stock were surrendered by Krish S. Krishnan and 12,056 shares by his spouse for tax withholding purposes, reducing their direct beneficial ownership of common stock.

Future Outlook

New stock options and restricted stock units granted to Krish S. Krishnan and his spouse are set to vest in annual installments starting February 27, 2027, with stock options expiring on February 26, 2036, indicating long-term incentive alignment.

Industry Context

StockSavvy.ai notes that insider equity transactions, such as those reported by Krystal Biotech's CEO, are common mechanisms for executive compensation and long-term incentive alignment across the biotechnology industry. The vesting of performance-based units, in particular, signals the achievement of pre-defined corporate objectives.

Related Party Transactions

• Transactions involving Suma M. Krishnan, the spouse of the Reporting Person, are reported as indirect beneficial ownership.
• Holdings in the Krishnan Spousal Trust and Krishnan Family Trust are reported as indirect beneficial ownership, with the Reporting Person and his spouse having joint voting and investment control over the Family Trust.

Stakeholder Impact

• Shareholders: The vesting and new grants of equity awards align the interests of the CEO with shareholders, incentivizing long-term company performance. Tax withholdings represent a routine disposition of shares.
• Employees: The compensation structure reflects standard executive incentive programs, potentially setting a precedent for other key personnel.

Next Steps

• Future annual vesting installments for the newly granted stock options and restricted stock units will commence on February 27, 2027.

Key Dates

Recommendation

This Form 4 details routine executive compensation activities, including the vesting of equity awards and new grants. While these transactions align management's interests with shareholders, they do not provide new fundamental information to warrant a change in investment thesis. The stock price used for tax withholding is a snapshot, not a forward-looking valuation.

Keywords

Krystal Biotech, KRYS, SEC Form 4, Insider Trading, Equity Compensation, Restricted Stock Units, Performance Stock Units, Stock Options, Executive Compensation, Biotechnology